JP2024538669A5 - - Google Patents

Info

Publication number
JP2024538669A5
JP2024538669A5 JP2024520079A JP2024520079A JP2024538669A5 JP 2024538669 A5 JP2024538669 A5 JP 2024538669A5 JP 2024520079 A JP2024520079 A JP 2024520079A JP 2024520079 A JP2024520079 A JP 2024520079A JP 2024538669 A5 JP2024538669 A5 JP 2024538669A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
amino acid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538669A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/122556 external-priority patent/WO2023051683A1/zh
Publication of JP2024538669A publication Critical patent/JP2024538669A/ja
Publication of JP2024538669A5 publication Critical patent/JP2024538669A5/ja
Pending legal-status Critical Current

Links

JP2024520079A 2021-09-29 2022-09-29 抗lag3二重特異性抗体、医薬組成物、及び使用 Pending JP2024538669A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111149114 2021-09-29
CN202111149114.9 2021-09-29
PCT/CN2022/122556 WO2023051683A1 (zh) 2021-09-29 2022-09-29 抗lag3双特异性抗体、药物组合物及用途

Publications (2)

Publication Number Publication Date
JP2024538669A JP2024538669A (ja) 2024-10-23
JP2024538669A5 true JP2024538669A5 (cg-RX-API-DMAC7.html) 2025-10-07

Family

ID=85770153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024519329A Pending JP2024536881A (ja) 2021-09-29 2022-09-28 抗lag3抗体、医薬組成物、及び使用
JP2024520079A Pending JP2024538669A (ja) 2021-09-29 2022-09-29 抗lag3二重特異性抗体、医薬組成物、及び使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2024519329A Pending JP2024536881A (ja) 2021-09-29 2022-09-28 抗lag3抗体、医薬組成物、及び使用

Country Status (11)

Country Link
US (2) US20250042995A1 (cg-RX-API-DMAC7.html)
EP (2) EP4410835A4 (cg-RX-API-DMAC7.html)
JP (2) JP2024536881A (cg-RX-API-DMAC7.html)
KR (2) KR20240083095A (cg-RX-API-DMAC7.html)
CN (2) CN115873116B (cg-RX-API-DMAC7.html)
AU (2) AU2022355381A1 (cg-RX-API-DMAC7.html)
CA (2) CA3233205A1 (cg-RX-API-DMAC7.html)
IL (2) IL311738A (cg-RX-API-DMAC7.html)
MX (2) MX2024003936A (cg-RX-API-DMAC7.html)
WO (2) WO2023051621A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202403273B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
CN117159703B (zh) * 2023-11-02 2024-04-02 正大天晴(广州)医药有限公司 含抗lag-3抗体的药物组合物及其用途
WO2025201450A1 (zh) * 2024-03-27 2025-10-02 康方汇科(上海)生物有限公司 药物组合及用途
WO2025232896A1 (zh) * 2024-05-10 2025-11-13 康方汇科(上海)生物有限公司 药物组合及用途
CN120518768B (zh) * 2025-05-30 2025-12-30 中国人民解放军军事科学院军事医学研究院 抗lag-3的单克隆抗体、抗pd-1与lag-3的双特异性抗体、制备方法及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AR091649A1 (es) * 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
WO2015116539A1 (en) 2014-01-28 2015-08-06 Bristol-Myers Squibb Company Anti-lag-3 antibodies to treat hematological malignancies
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN106632674B (zh) 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
BR112018012352A2 (pt) * 2015-12-16 2018-12-11 Merck Sharp & Dohme Corp. anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CA3026151A1 (en) * 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
SG11201811184UA (en) * 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
US20200079850A1 (en) * 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
WO2018222718A1 (en) * 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
EP3714901A4 (en) * 2017-12-22 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
CN110615840A (zh) * 2018-06-19 2019-12-27 信达生物制药(苏州)有限公司 全人源的抗lag-3抗体及其应用
US12173070B2 (en) * 2018-08-21 2024-12-24 Abl Bio Inc. Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN112079925B (zh) * 2019-06-13 2025-04-25 上海健信生物医药科技有限公司 靶向lag-3的抗体和双特异性抗体及其用途
CN114206931B (zh) * 2019-09-30 2024-06-04 四川科伦博泰生物医药股份有限公司 抗pd-1抗体及其用途
MX2022006330A (es) * 2019-11-25 2022-08-17 Akeso Biopharma Inc Anticuerpo biespecífico anti-pd-1 anti-vegfa, composición farmacéutica y uso del mismo.
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
CN113348182B (zh) * 2019-12-30 2022-07-12 上海海路生物技术有限公司 Lag-3抗体及其医药用途
JP7692918B6 (ja) * 2020-01-21 2025-07-17 上海復宏漢霖生物技術股▲フン▼有限公司 抗lag3モノクローナル抗体、その製造方法および使用
CN118530342A (zh) * 2021-03-12 2024-08-23 中山康方生物医药有限公司 降低免疫细胞分泌il-8和/或il-6的水平的方法
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE

Similar Documents

Publication Publication Date Title
JP2023504003A5 (cg-RX-API-DMAC7.html)
JP2022515318A5 (cg-RX-API-DMAC7.html)
JP2024536881A5 (cg-RX-API-DMAC7.html)
JP2021524249A5 (cg-RX-API-DMAC7.html)
JP2024509018A5 (cg-RX-API-DMAC7.html)
JP2017519759A5 (cg-RX-API-DMAC7.html)
JP2023539501A5 (cg-RX-API-DMAC7.html)
RU2013152164A (ru) Анти-в7-н3-антитело
JP2026041845A5 (cg-RX-API-DMAC7.html)
JP2023516004A5 (cg-RX-API-DMAC7.html)
JP2007515165A5 (cg-RX-API-DMAC7.html)
JP2025038088A5 (cg-RX-API-DMAC7.html)
JP2025511289A5 (cg-RX-API-DMAC7.html)
JP2022545741A5 (cg-RX-API-DMAC7.html)
JP2025507817A5 (cg-RX-API-DMAC7.html)
JP2024542192A5 (cg-RX-API-DMAC7.html)
JP2025511288A5 (cg-RX-API-DMAC7.html)
JP2020502233A5 (cg-RX-API-DMAC7.html)
JP2023518153A5 (cg-RX-API-DMAC7.html)
JP2023516941A5 (cg-RX-API-DMAC7.html)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
CN111712521A (zh) Cd38蛋白抗体及其应用
JP2024020436A5 (cg-RX-API-DMAC7.html)
JP2025503229A5 (cg-RX-API-DMAC7.html)
JP2024532836A5 (cg-RX-API-DMAC7.html)